If HIV patients stop taking tesamorelin and switch to a dummy pill, their dangerous belly fat quickly returns to previous levels.

Scientific Claim

Switching from tesamorelin to placebo reverses the reduction in visceral adipose tissue in HIV-infected patients with central fat accumulation.

Original Statement

“The initial improvements over 6 months in VAT were rapidly lost in those switching from tesamorelin to placebo.”

From study:Unknown Title

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The study is a randomized controlled trial with a control group, which allows for causal inference. The verb 'reverses' is appropriate for this design.

Evidence from Studies

Supporting (1)

Unknown Title

Randomized Controlled Trial

Human

When patients stopped taking tesamorelin and got a placebo instead, the belly fat they lost came right back — so stopping the drug undoes its benefits.

Contradicting (0)

No contradicting evidence found

Source Study

Unknown Title

Score: 81

DOI: 10.1097/QAI.0b013e3181cbdaff

Similar Assertions

Continuing tesamorelin for a full year helps HIV patients with belly fat lose nearly 18% of their dangerous internal belly fat, with no loss of benefit over time.

91%

A hormone treatment called tesamorelin decreases belly fat by 42 square centimeters more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

91%

A drug called tesamorelin helps HIV patients with belly fat buildup lose about 11% of their dangerous internal belly fat in six months, while those on a dummy pill lose almost none.

91%

A drug called tesamorelin helps reduce belly fat deep inside the abdomen for people with HIV who are on medication, making their belly fat decrease by about 15% compared to those not taking the drug. This finding is from the abstract summary - full study details were not available

90%

In a randomized, double-blind, placebo-controlled trial of 404 HIV-infected patients with abdominal fat accumulation, tesamorelin reduced visceral adipose tissue by 10.9% (21 cm²) after 6 months compared to less than 1% in the placebo group, with concurrent reductions in waist circumference and trunk fat and increases in IGF-I levels.

88%